

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM853663

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	Release of Trademark Security Interests Recorded at Reel 5348, Frame 0242

## CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
Deutsche Bank AG New York Branch, as Collateral Agent		11/14/2023	Banking Corporation: GERMANY

## RECEIVING PARTY DATA

<b>Name:</b>	Questcor Pharmaceuticals, Inc.
<b>Street Address:</b>	26118 Research Road
<b>City:</b>	Hayward
<b>State/Country:</b>	CALIFORNIA
<b>Postal Code:</b>	94545
<b>Entity Type:</b>	Corporation: CALIFORNIA
<b>Name:</b>	Cadence Pharmaceuticals, Inc.
<b>Street Address:</b>	12481 High Bluff Drive, Suite 200
<b>City:</b>	San Diego
<b>State/Country:</b>	CALIFORNIA
<b>Postal Code:</b>	92130
<b>Entity Type:</b>	Corporation: CALIFORNIA

## PROPERTY NUMBERS Total: 7

Property Type	Number	Word Mark
Registration Number:	2255322	ACTHAR GEL
Registration Number:	2810894	QUESTCOR PHARMACEUTICALS, INC.
Registration Number:	2756559	QUESTCOR
Registration Number:	3955489	OFIRMEV
Registration Number:	3706950	CADENCE
Registration Number:	3093264	ACTHAR
Registration Number:	4433497	

## CORRESPONDENCE DATA

Fax Number:

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

Phone: 2136207848

TRADEMARK

**Email:** iprecordations@whitecase.com  
**Correspondent Name:** Justine Lu/White & Case LLP  
**Address Line 1:** 555 South Flower Street, Suite 2700  
**Address Line 4:** Los Angeles, CALIFORNIA 90071

**ATTORNEY DOCKET NUMBER:** 1111779-3049-S216

**NAME OF SUBMITTER:** Justine Lu

**SIGNATURE:** /Justine Lu/

**DATE SIGNED:** 11/15/2023

**Total Attachments: 4**

source=MNK - Trademark Release (2014 CA - 0242) (Executed)#page1.tif

source=MNK - Trademark Release (2014 CA - 0242) (Executed)#page2.tif

source=MNK - Trademark Release (2014 CA - 0242) (Executed)#page3.tif

source=MNK - Trademark Release (2014 CA - 0242) (Executed)#page4.tif

RELEASE OF TRADEMARK SECURITY INTERESTS, dated as of November 14, 2023 (this “Release”), by Deutsche Bank AG New York Branch, as collateral agent under the Credit Agreement (as defined below) (in such capacity, the “Collateral Agent”) in favor of **QUESTCOR PHARMACEUTICALS, INC.**, a California corporation and **CADENCE PHARMACEUTICALS, INC.**, a Delaware corporation (each a “Pledgor”, collectively the “Pledgors”). Capitalized terms used herein and not otherwise defined shall have the meanings assigned to such terms in the U.S. Collateral Agreement, referred to below.

A. Reference is made to (i) the U.S. Collateral Agreement, dated as of March 19, 2014 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “U.S. Collateral Agreement”), among MALLINCKRODT INTERNATIONAL FINANCE S.A., a public limited liability company (société anonyme) incorporated under the laws of the Grand Duchy of Luxembourg, having its registered office at 124, boulevard de la Pétrusse, L-2330 Luxembourg, and registered with the Luxembourg Trade and Companies Register (R.C.S Luxembourg) under number B 172.865 (the “Lux Borrower”), MALLINCKRODT CB LLC, a Delaware limited liability company (the “Co-Borrower”, and together with the Lux Borrower, the “Borrowers”), Mallinckrodt Finance GmbH (the “Swiss Finco”), each other Subsidiary Loan Party listed on the signature pages thereof and each other Subsidiary Loan Party that becomes a party thereto after the Closing Date (as defined therein) and DEUTSCHE BANK AG NEW YORK BRANCH, as collateral agent (together with its successors and assigns in such capacity, the “Collateral Agent”) for the Secured Parties (as defined therein) and (ii) the Notice of Grant of Security Interest in Trademarks, dated as of August 14, 2014, among the Pledgors party thereto and the Collateral Agent (such documents set forth in clauses (i) and (ii) the “Security Documents”).

B. Pursuant to the Security Documents, the Pledgors granted to the Collateral Agent, for the benefit of the Secured Parties, a security interest in all right, title and interest of the Pledgors in, to and under, among other things, the Trademarks of the Pledgors, including those set forth on Schedule I hereto (collectively, the “Trademark Collateral”), which security interest was recorded with the United States Patent and Trademark Office on August 20, 2014 at Reel/Frame 5348/0242.

Accordingly, for good and valuable consideration, the receipt and sufficiency of the which are hereby acknowledged, in accordance with the U.S. Collateral Agreement, the Collateral Agent does hereby release, relinquish and discharge any and all security interests it has against the Trademark Collateral. If and to the extent that the Collateral Agent has acquired any right, title or interest in and to the Trademark Collateral, the Collateral Agent, without representation or warranty of any kind, hereby re-transfers, re-conveys and re-assigns such right, title or interest to the applicable Pledgor. The Collateral Agent acknowledges and agrees that the Issuers or their designees shall, on behalf of the Collateral Agent (at the Issuers’ sole cost and expenses), make filings, including of this Release, with the United States Patent and Trademark Office and other necessary filings to evidence the release and termination of the Collateral Agent’s security interests in the Trademark Collateral. The Collateral Agent agrees to take all further actions, and provide to each Pledgor and its successors, assigns or other legal representatives, all such cooperation and


assistance (including, without limitation, the execution and delivery of any and all documents or other instruments), reasonably requested by the Pledgors, at the Pledgors' sole cost and expense, to more fully and effectively effectuate the purposes of this Release.


THIS RELEASE SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK AND SHALL BE BINDING UPON THE COLLATERAL AGENT'S REPRESENTATIVES, SUCCESSORS, ASSIGNS AND TRANSFEREES.

[The remainder of this page intentionally left blank]

IN WITNESS WHEREOF, the Collateral Agent has caused this Release to be duly executed as of the day and year first above written.

DEUTSCHE BANK AG NEW YORK BRANCH,  
as Collateral Agent

By:   
Name: Philip Tancorra  
Title: Director

By:   
Name: Lauren Danbury  
Title: Vice President

[SIGNATURE PAGE TO RELEASE OF TRADEMARK SECURITY INTERESTS]

Schedule I  
Trademarks

1	<b>Serial #:</b> <u>75445831</u> <b>Mark:</b> ACTHAR GEL	<b>Filing Dt:</b> 03/06/1998	<b>Reg #:</b> <u>2255322</u>	<b>Reg. Dt:</b> 06/22/1999
2	<b>Serial #:</b> <u>75802117</u> <b>Mark:</b> QUESTCOR PHARMACEUTICALS, INC.	<b>Filing Dt:</b> 09/17/1999	<b>Reg #:</b> <u>2810894</u>	<b>Reg. Dt:</b> 02/03/2004
3	<b>Serial #:</b> <u>75867216</u> <b>Mark:</b> QUESTCOR	<b>Filing Dt:</b> 12/09/1999	<b>Reg #:</b> <u>2756559</u>	<b>Reg. Dt:</b> 08/26/2003
4	<b>Serial #:</b> <u>77857487</u> <b>Mark:</b> OFIRMEV	<b>Filing Dt:</b> 10/26/2009	<b>Reg #:</b> <u>3955489</u>	<b>Reg. Dt:</b> 05/03/2011
5	<b>Serial #:</b> <u>78521118</u> <b>Mark:</b> CADENCE	<b>Filing Dt:</b> 11/22/2004	<b>Reg #:</b> <u>3706950</u>	<b>Reg. Dt:</b> 11/03/2009
6	<b>Serial #:</b> <u>78649502</u> <b>Mark:</b> ACTHAR	<b>Filing Dt:</b> 06/13/2005	<b>Reg #:</b> <u>3093264</u>	<b>Reg. Dt:</b> 05/16/2006
7	<b>Serial #:</b> <u>85672800</u> <b>Mark:</b>	<b>Filing Dt:</b> 07/10/2012	<b>Reg #:</b> <u>4433497</u>	<b>Reg. Dt:</b> 11/12/2013